NASH, or non-alcoholic steatohepatitis, has been a hot space for pharma over the last few years, prompting major players to pour big bucks into dealmaking. Yet, as the first drugs reach late stages and near approval, companies are taking a step back to see how the data read out.
At the same time, preclinical and early-stage NASH assets are beginning to mature and bring with them the promise of a new wave of NASH drugs and more M&A activity.
BioPharma Dive is taking a deeper look at how this market is changing, the challenges drugmakers will face if they reach commercialization and the shifting market sentiment, including a conversation with a biotech exploring the genetics of the disease.
3 market-busting hurdles to NASH commercialization
With the first NASH drugs expected to win approval over the next two to three years, drugmakers will face several major barriers to market entry. Read More »
Regeneron's Aris Baras on probing the genome to find drugs for NASH
Researchers at Regeneron found a genetic variant associated with lower risk of chronic liver disease. Lacking the tools to turn the discovery into a drug, the biotech partnered with Alnylam. Read More »
NASH drug pipeline headed toward uncertain market
The fatty liver disease has dozens of treatments in the global pipeline. But investors are treading lightly, casting doubt on the market opportunity. Read More »
Pharma turn to NASH unlikely to mirror meteoric rise of hep C
Hopes of a hepatitis C-sized market could be dashed by the complexity of and challenges in diagnosing the lesser-known liver disease. Read More »
After a flurry, NASH deals put on pause
After several years of dealmaking in the liver disease space, the industry waits for the next wave of assets to mature. Read More »